TEST:

FirstLook Lung

"City of Hope...and DELFI Diagnostics...today announced a collaboration to utilize DELFI's FirstLook Lung, a blood-based lung cancer screening test, in a City of Hope clinical study to help improve screening rates in underserved communities in Los Angeles County. The test will be offered free of charge to eligible trial participants...Funded by a Discovery Boost grant from the American Cancer Society, awarded to Dan Raz...and the trial's principal investigator, the study that will evaluate use of the FirstLook Lung test to improve lung cancer screening rates in disadvantaged communities in the Los Angeles area. DELFI will make its liquid biopsy screening test, which will be submitted to the Food and Drug Administration for approval, available at various study locations, including City of Hope Antelope Valley...and ParkTree Community Health Center..."

"DELFI Diagnostics, Inc...today announced multiple upcoming poster and oral presentations at the American Association for Cancer Research (AACR) Annual Meeting, taking place in San Diego, California, from April 5-10, 2024. DELFI and independent researchers will highlight the performance of the company's next-generation, fragmentomics-based liquid biopsy platform to help detect early cancer and monitor treatment response."

"DELFI Diagnostics, Inc...announced support for the recently introduced Lung Cancer Screening and Prevention Act (H.R. 6693)...The proposed legislation would grant the Centers for Medicare & Medicaid Services (CMS) the authority to review U.S. Food and Drug Administration (FDA) approved or cleared new lung cancer screening tests as preventive services under the Agency's existing standards for coverage."

"DELFI Diagnostics, Inc...announced...the initial commercial introduction of FirstLook Lung. FirstLook is a blood test that offers a convenient, accurate and personalized result by determining the likelihood of detecting lung cancer through low-dose CT (LDCT), with a negative predictive value (NPV) of 99.7 percent."